U095 Practical Approach to the Diagnosis and Management of Cutaneous Graft Versus Host Disease
DESCRIPTION
Patients who receive allogeneic hematopoietic stem cell transplantation are at significant risk of developing cutaneous graft versus host disease (GVHD). In this session, we will provide practical tips to prepare dermatologists in all practice environments to more confidently approach the evaluation and management of acute and chronic skin GVHD. We will also present updated 2025 NIH response assessment guidelines for cutaneous chronic GVHD.
LEARNING OBJECTIVES
Diagnose acute graft versus host disease (GVHD) of the skin and review a comprehensive differential diagnosis for patients who present with skin eruptions after allogeneic hematopoietic stem cell transplant.
Recognize diagnostic features of cutaneous and mucocutaneous chronic GVHD, differentiate epidermal and sclerotic phenotypes, and tailor site-specific management.
Apply updated 2025 NIH response criteria for cutaneous chronic GVHD, including separate epidermal and sclerotic BSA assessment and new sclerosis severity scales for clinically meaningful response.
DIRECTOR
Silvina Pugliese, MD, FAAD
SPEAKER
Alina Markova, MD, FAAD
DISCLOSURES
Alina Markova, MD, FAAD
Amryt Pharma – Investigator(Grants/Research Funding); AstraZeneca – Consultant (1099 relationship)(Fees); Incyte Corporation – Investigator(Grants/Research Funding); Janssen Biotech – Investigator(Grants/Research Funding); Kintara Therapeutics, Inc. – Investigator(Grants/Research Funding); National Institutes of Health – Investigator(Grants/Research Funding); Novartis – Investigator(Grants/Research Funding); Novocure – Investigator(Grants/Research Funding); Sanofi Genzyme – Advisory Board(Honoraria); Treeline – Consultant (1099 relationship)(Honoraria); UpToDate – Other(Patent royalties or other compensation for Intellectual Property Rights);
Silvina Pugliese, MD, FAAD
Exelixis – Other(No Compensation Received); Regeneron Pharmaceuticals Inc – Advisory Board(Honoraria); Veradermics – Consultant (1099 relationship)(Fees);